Epidemiology and burden of HPV-related disease

Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and nec...

Full description

Saved in:
Bibliographic Details
Published inBest practice & research. Clinical obstetrics & gynaecology Vol. 47; pp. 14 - 26
Main Authors Serrano, Beatriz, Brotons, María, Bosch, Francesc Xavier, Bruni, Laia
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.02.2018
Subjects
Online AccessGet full text
ISSN1521-6934
1532-1932
1532-1932
DOI10.1016/j.bpobgyn.2017.08.006

Cover

Abstract Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction. •HPV is responsible of 4.5% (630,000) of all new cancer cases worldwide.•Cervical cancer is the fourth most frequent cancer among women and the fourth leading cause of cancer deaths worldwide.•HPV16 is consistently the most frequent genotype in all HPV-related cancer sites.•Universal HPV vaccination could prevent between 70% and 90% of HPV-related disease.•Increasing trends in HPV-related anal and head and neck cancers have been observed in the last decade.
AbstractList Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction. •HPV is responsible of 4.5% (630,000) of all new cancer cases worldwide.•Cervical cancer is the fourth most frequent cancer among women and the fourth leading cause of cancer deaths worldwide.•HPV16 is consistently the most frequent genotype in all HPV-related cancer sites.•Universal HPV vaccination could prevent between 70% and 90% of HPV-related disease.•Increasing trends in HPV-related anal and head and neck cancers have been observed in the last decade.
Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction.
Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction.Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction.
Author Bosch, Francesc Xavier
Brotons, María
Bruni, Laia
Serrano, Beatriz
Author_xml – sequence: 1
  givenname: Beatriz
  surname: Serrano
  fullname: Serrano, Beatriz
  email: bscarro@iconcologia.net
  organization: Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d’Oncologia (ICO) – Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
– sequence: 2
  givenname: María
  surname: Brotons
  fullname: Brotons, María
  email: mbrotons@idibell.cat
  organization: Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d’Oncologia (ICO) – Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
– sequence: 3
  givenname: Francesc Xavier
  surname: Bosch
  fullname: Bosch, Francesc Xavier
  email: x.bosch@iconcologia.net
  organization: Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d’Oncologia (ICO) – Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
– sequence: 4
  givenname: Laia
  orcidid: 0000-0003-3943-0326
  surname: Bruni
  fullname: Bruni, Laia
  email: lbruni@iconcologia.net
  organization: Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d’Oncologia (ICO) – Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29037457$$D View this record in MEDLINE/PubMed
BookMark eNqNkEFLwzAUx4NM3Jx-BKVHL60vSds1iIgMdYKgB_Ua0uR1ZHbJTDph396OzYsXveTl8Pv9H-9_TAbOOyTkjEJGgZaXi6xe-Xq-cRkDOsmgygDKAzKiBWcpFZwNtn9G01LwfEiOY1wAcC5YcUSGTACf5MVkRLK7lTW4tL71802inEnqdTDoEt8ks5f3NGCrOjSJsRFVxBNy2Kg24ul-jsnb_d3rdJY-PT88Tm-fUp1T0aUGwWhseCmaSoOp8qqkgBpwYlBwigXWRkEDuqhFVTHFlS5y0z-GYUNFzsfkYpe7Cv5zjbGTSxs1tq1y6NdRUtGfBj3IevR8j67rJRq5Cnapwkb-3NgDVztABx9jwEZq26nOetcFZVtJQW4blQu5b1RuG5VQyb7R3i5-2T8L_vJudh72NX1ZDDJqi06jsQF1J423fyZc_0rQrXVWq_YDN__wvwH0wqd9
CitedBy_id crossref_primary_10_1038_s41598_022_17237_5
crossref_primary_10_2147_CMAR_S326544
crossref_primary_10_3390_pathogens9040300
crossref_primary_10_1186_s12903_024_04998_w
crossref_primary_10_1097_INF_0000000000002437
crossref_primary_10_1093_milmed_usz403
crossref_primary_10_3892_mmr_2019_10847
crossref_primary_10_1186_s12905_023_02279_2
crossref_primary_10_1371_journal_pone_0308599
crossref_primary_10_2147_IJGM_S308215
crossref_primary_10_1016_j_puhe_2021_05_012
crossref_primary_10_2174_0113862073263350231107105959
crossref_primary_10_1080_07853890_2024_2304649
crossref_primary_10_1128_mbio_02121_23
crossref_primary_10_3390_ijerph21030307
crossref_primary_10_1016_j_vaccine_2024_126177
crossref_primary_10_17116_stomat202310203116
crossref_primary_10_1186_s12889_023_15334_2
crossref_primary_10_17650_2313_805X_2021_11_2_31_40
crossref_primary_10_3390_cancers11060820
crossref_primary_10_1542_peds_2019_4035
crossref_primary_10_1016_j_vaccine_2024_02_033
crossref_primary_10_1007_s11547_021_01377_1
crossref_primary_10_1016_j_jiph_2023_04_018
crossref_primary_10_2807_1560_7917_ES_2019_24_7_1700857
crossref_primary_10_1016_j_vaccine_2022_10_022
crossref_primary_10_1007_s13187_024_02555_1
crossref_primary_10_22207_JPAM_19_1_14
crossref_primary_10_1016_j_ijid_2024_107094
crossref_primary_10_1149_1945_7111_ad8fd7
crossref_primary_10_1016_j_yexmp_2019_104314
crossref_primary_10_3390_vaccines10071054
crossref_primary_10_1136_bmjopen_2017_021170
crossref_primary_10_1021_acs_jmedchem_1c01567
crossref_primary_10_17116_molgen20213904139
crossref_primary_10_1016_j_lana_2024_100689
crossref_primary_10_1186_s12885_020_07452_6
crossref_primary_10_1007_s10552_024_01852_w
crossref_primary_10_3389_fpubh_2022_922587
crossref_primary_10_1002_jmv_29282
crossref_primary_10_1016_j_vaccine_2022_02_042
crossref_primary_10_5937_smclk5_48169
crossref_primary_10_1111_apa_17225
crossref_primary_10_1002_jmv_26690
crossref_primary_10_2174_2211536608666191026115045
crossref_primary_10_3390_biology10080794
crossref_primary_10_1186_s12992_022_00812_w
crossref_primary_10_1007_s10096_024_04933_5
crossref_primary_10_1016_j_jsamd_2021_100411
crossref_primary_10_1016_j_genrep_2020_100871
crossref_primary_10_4103_joc_joc_70_24
crossref_primary_10_1007_s10552_021_01550_x
crossref_primary_10_1016_j_tvr_2023_200263
crossref_primary_10_3390_cancers14174339
crossref_primary_10_3889_oamjms_2022_8491
crossref_primary_10_1017_S0950268819000621
crossref_primary_10_1111_codi_15320
crossref_primary_10_1186_s12885_022_09582_5
crossref_primary_10_1016_j_micpath_2022_105747
crossref_primary_10_4103_jehp_jehp_1350_23
crossref_primary_10_1016_j_bjid_2022_102734
crossref_primary_10_1080_21645515_2021_2007014
crossref_primary_10_17816_1728_2802_2022_26_3_267_276
crossref_primary_10_1007_s13353_024_00883_y
crossref_primary_10_1159_000518758
crossref_primary_10_1055_s_0042_1756479
crossref_primary_10_3389_fmed_2022_932196
crossref_primary_10_1016_j_reuma_2023_07_001
crossref_primary_10_1016_j_aprim_2023_102597
crossref_primary_10_1038_s41598_023_44365_3
crossref_primary_10_1002_cam4_2697
crossref_primary_10_1016_j_archoralbio_2022_105526
crossref_primary_10_1136_sextrans_2022_055447
crossref_primary_10_1002_2211_5463_12987
crossref_primary_10_1186_s12916_024_03686_4
crossref_primary_10_14777_uti_2448030015
crossref_primary_10_1016_j_abb_2023_109716
crossref_primary_10_31631_2073_3046_2020_19_2_110_118
crossref_primary_10_1002_jmv_29184
crossref_primary_10_1016_j_molimm_2024_05_006
crossref_primary_10_1136_bmjgh_2019_001886
crossref_primary_10_1007_s42764_021_00038_x
crossref_primary_10_3389_fonc_2022_864820
crossref_primary_10_1007_s13187_021_02018_x
crossref_primary_10_1007_s40944_024_00815_y
crossref_primary_10_1016_j_semradonc_2021_04_001
crossref_primary_10_1016_S2352_3018_18_30179_6
crossref_primary_10_1186_s12929_022_00864_5
crossref_primary_10_3389_fpubh_2024_1440480
crossref_primary_10_1177_10105395211006600
crossref_primary_10_1002_ajmg_a_60684
crossref_primary_10_1016_j_lfs_2021_120268
crossref_primary_10_1016_j_vaccine_2020_03_035
crossref_primary_10_5858_arpa_2023_0285_OA
crossref_primary_10_1016_j_vhri_2022_06_006
crossref_primary_10_1177_2333393618760337
crossref_primary_10_3390_vaccines10010010
crossref_primary_10_1016_j_jiph_2020_05_024
crossref_primary_10_1080_01443615_2018_1493441
crossref_primary_10_2174_0113816128317605240628063731
crossref_primary_10_1016_j_medcli_2021_12_014
crossref_primary_10_1177_0194599820941499
crossref_primary_10_4111_icu_20220318
crossref_primary_10_3389_fcell_2021_677867
crossref_primary_10_1016_j_jpba_2020_113249
crossref_primary_10_32635_2176_9745_RBC_2025v71n1_4928
crossref_primary_10_4274_eamr_galenos_2021_62634
crossref_primary_10_3390_microorganisms13040734
crossref_primary_10_4014_jmb_2304_04009
crossref_primary_10_1186_s12905_021_01320_6
crossref_primary_10_1371_journal_pone_0268104
crossref_primary_10_3390_vaccines8010074
crossref_primary_10_1080_0284186X_2021_1885056
crossref_primary_10_1016_j_ygeno_2021_09_006
crossref_primary_10_1097_MD_0000000000036822
crossref_primary_10_1016_j_micpath_2023_106302
crossref_primary_10_3390_cancers16112107
crossref_primary_10_3390_vaccines9060643
crossref_primary_10_1016_j_ijid_2021_06_006
crossref_primary_10_3390_vaccines11061126
crossref_primary_10_1016_j_vaccine_2021_11_046
crossref_primary_10_1016_j_vaccine_2018_09_035
crossref_primary_10_1080_21645515_2018_1526559
crossref_primary_10_1080_21645515_2024_2425146
crossref_primary_10_5935_2526_8732_20220328
crossref_primary_10_1186_s12985_021_01551_x
crossref_primary_10_1002_lio2_1294
crossref_primary_10_1016_j_ejogrb_2024_09_003
crossref_primary_10_1002_jmv_27582
crossref_primary_10_1111_jphd_12350
crossref_primary_10_2147_IJWH_S474571
crossref_primary_10_1016_j_ejogrb_2018_09_023
crossref_primary_10_3390_v14050980
crossref_primary_10_3390_v16091357
crossref_primary_10_3390_vaccines11061038
crossref_primary_10_1080_21645515_2019_1691413
crossref_primary_10_1002_jmv_70299
crossref_primary_10_6061_clinics_2018_e486s
crossref_primary_10_1016_j_bbagrm_2019_01_001
crossref_primary_10_3390_biomedicines12122699
crossref_primary_10_1016_j_jmh_2022_100102
crossref_primary_10_15406_jcpcr_2021_12_00477
crossref_primary_10_3390_ijerph18030963
crossref_primary_10_3389_fped_2022_1057454
crossref_primary_10_1016_j_molstruc_2020_129865
crossref_primary_10_3389_fmed_2022_1020760
crossref_primary_10_3892_or_2024_8733
crossref_primary_10_1002_ijc_31881
crossref_primary_10_3390_photonics9060408
crossref_primary_10_3390_molecules26144214
crossref_primary_10_1038_s41598_020_64268_x
crossref_primary_10_1051_bioconf_20248601029
crossref_primary_10_1016_j_vaccine_2019_06_001
crossref_primary_10_1016_j_mgene_2020_100720
crossref_primary_10_1177_09564624221146605
crossref_primary_10_1128_jvi_00663_22
crossref_primary_10_1136_sextrans_2022_055484
crossref_primary_10_1186_s12879_024_09410_0
crossref_primary_10_1136_sextrans_2024_056255
crossref_primary_10_18632_oncotarget_25136
crossref_primary_10_3389_fimmu_2025_1535261
crossref_primary_10_3390_bioengineering9120806
crossref_primary_10_1080_21645515_2022_2127983
crossref_primary_10_1158_2326_6066_CIR_19_0315
crossref_primary_10_1515_hsz_2019_0408
crossref_primary_10_1016_j_jcvp_2022_100105
crossref_primary_10_1002_jmv_29784
crossref_primary_10_3390_ijms252312991
crossref_primary_10_1177_10732748251318386
crossref_primary_10_1016_j_jvacx_2024_100551
crossref_primary_10_26442_20795696_2023_1_202070
crossref_primary_10_3389_fonc_2021_712553
crossref_primary_10_1016_j_ebiom_2023_104577
crossref_primary_10_1080_07853890_2025_2468261
crossref_primary_10_17749_2313_7347_2019_13_2_132_154
crossref_primary_10_1590_1980_549720200094
crossref_primary_10_33880_ejfm_2023120404
crossref_primary_10_3390_vaccines8030391
crossref_primary_10_1016_j_heliyon_2020_e04625
crossref_primary_10_1159_000509669
crossref_primary_10_1016_j_bioelechem_2024_108861
crossref_primary_10_1093_infdis_jiy432
crossref_primary_10_1136_jitc_2023_007158
crossref_primary_10_3390_vaccines12060611
crossref_primary_10_1111_ijn_13228
crossref_primary_10_17650_2219_4614_2023_15_2_25_37
crossref_primary_10_1093_infdis_jiad204
crossref_primary_10_1177_25151355241308313
crossref_primary_10_3390_joma2010004
crossref_primary_10_1186_s12985_024_02497_6
crossref_primary_10_3390_vaccines9050535
crossref_primary_10_1371_journal_pone_0260808
crossref_primary_10_3389_fpubh_2022_920578
crossref_primary_10_3390_vaccines11010022
crossref_primary_10_1002_ijc_32195
crossref_primary_10_1016_j_virol_2022_09_004
crossref_primary_10_1016_j_vaccine_2019_12_016
crossref_primary_10_1080_14760584_2022_2129615
crossref_primary_10_1155_2020_8838317
crossref_primary_10_1177_10732748231202925
crossref_primary_10_1186_s12905_024_03249_y
crossref_primary_10_33417_tsh_1052993
crossref_primary_10_1002_cam4_6875
crossref_primary_10_1158_2159_8290_CD_22_0776
crossref_primary_10_1002_ohn_535
crossref_primary_10_2217_fvl_2018_0137
crossref_primary_10_1155_2022_8752388
crossref_primary_10_1080_10826068_2022_2065686
crossref_primary_10_1002_rmv_2537
crossref_primary_10_1016_j_pvr_2019_100172
crossref_primary_10_1186_s12920_020_0700_7
crossref_primary_10_26416_Gine_44_2_2024_9671
crossref_primary_10_1002_jmv_28351
crossref_primary_10_3389_fmicb_2018_03022
crossref_primary_10_1371_journal_pone_0281976
crossref_primary_10_1016_j_ejogrb_2018_05_009
crossref_primary_10_31631_2073_3046_2020_20_2_110_118
crossref_primary_10_1016_j_jogoh_2025_102945
crossref_primary_10_1128_jvi_01819_22
crossref_primary_10_1007_s13193_024_02184_6
crossref_primary_10_1136_bmjopen_2022_069616
crossref_primary_10_1111_jog_14276
crossref_primary_10_1186_s13643_019_0983_y
crossref_primary_10_1016_j_isci_2024_110155
crossref_primary_10_1038_s41598_025_86943_7
crossref_primary_10_1111_dth_15735
crossref_primary_10_1002_psc_70000
crossref_primary_10_1007_s10552_022_01642_2
crossref_primary_10_1097_NNR_0000000000000729
crossref_primary_10_1186_s13027_021_00403_1
crossref_primary_10_3389_fcimb_2022_1077651
crossref_primary_10_3390_vaccines10091398
crossref_primary_10_3390_vaccines12040421
crossref_primary_10_6061_clinics_2018_e551s
crossref_primary_10_1136_bmjgh_2024_018723
crossref_primary_10_1002_2211_5463_13666
crossref_primary_10_3390_vaccines11020284
crossref_primary_10_1080_21505594_2023_2237222
crossref_primary_10_1016_j_glmedi_2025_100182
crossref_primary_10_3390_v14081797
crossref_primary_10_3390_jmp1010003
crossref_primary_10_3390_pathogens14030221
crossref_primary_10_33204_mucosa_580103
crossref_primary_10_1111_jdv_17702
crossref_primary_10_3390_ijms21145020
crossref_primary_10_3389_fimmu_2020_02078
crossref_primary_10_1093_jncics_pkad068
crossref_primary_10_1097_MD_0000000000014436
crossref_primary_10_1177_13591053211073642
crossref_primary_10_1371_journal_pone_0250113
crossref_primary_10_1002_path_5236
crossref_primary_10_1016_j_coviro_2018_09_002
crossref_primary_10_5812_archcid_105620
crossref_primary_10_1016_j_medcle_2021_12_009
crossref_primary_10_1080_21645515_2022_2067421
crossref_primary_10_1007_s13337_019_00545_2
crossref_primary_10_1080_21645515_2023_2258569
crossref_primary_10_3390_ijms221810115
crossref_primary_10_1007_s10935_022_00697_w
crossref_primary_10_1080_08870446_2022_2090560
crossref_primary_10_1093_eurpub_ckad229
crossref_primary_10_3389_fmicb_2019_03116
crossref_primary_10_5812_apid_140119
crossref_primary_10_3390_cancers14133038
crossref_primary_10_1002_cncr_32986
crossref_primary_10_1016_j_tvr_2021_200231
crossref_primary_10_1038_s41467_023_37377_0
crossref_primary_10_1016_j_coviro_2021_02_002
crossref_primary_10_1089_photob_2020_4916
crossref_primary_10_3390_nu10020243
crossref_primary_10_1016_j_tranon_2025_102363
crossref_primary_10_1186_s12889_020_08840_0
crossref_primary_10_54097_hset_v19i_2845
crossref_primary_10_1136_bmjopen_2020_038531
crossref_primary_10_1016_j_meegid_2019_04_018
crossref_primary_10_3390_v13050727
crossref_primary_10_1002_slct_202200655
crossref_primary_10_1093_cid_ciab603
crossref_primary_10_1159_000508015
crossref_primary_10_1186_s12905_020_01035_0
crossref_primary_10_4103_npmj_npmj_265_23
crossref_primary_10_7759_cureus_57701
crossref_primary_10_1136_rmdopen_2019_001041
crossref_primary_10_1097_JS9_0000000000002117
crossref_primary_10_1016_j_humimm_2023_110724
crossref_primary_10_1080_10408398_2024_2414828
crossref_primary_10_1093_qjmed_hcae207
crossref_primary_10_1158_1940_6207_CAPR_19_0098
crossref_primary_10_1016_j_cegh_2024_101773
crossref_primary_10_3390_ijerph22030439
crossref_primary_10_1055_a_1976_9815
crossref_primary_10_14489_lcmp_2023_02_pp_046_059
crossref_primary_10_20517_2394_4722_2023_54
crossref_primary_10_3390_nu10040469
crossref_primary_10_1038_s41417_023_00682_3
crossref_primary_10_1016_j_ebiom_2020_103165
crossref_primary_10_1007_s10989_020_10089_5
crossref_primary_10_1002_jmv_70126
crossref_primary_10_3390_ijerph192315532
crossref_primary_10_1016_j_genrep_2024_101970
crossref_primary_10_1093_jnci_djad189
crossref_primary_10_3389_fonc_2023_1111778
crossref_primary_10_1016_j_critrevonc_2022_103675
crossref_primary_10_1128_mBio_03224_20
crossref_primary_10_3390_life13081775
crossref_primary_10_1016_j_vaccine_2020_11_029
crossref_primary_10_3390_ijms241411855
crossref_primary_10_1080_07399332_2021_1982945
crossref_primary_10_1186_s12939_019_1067_2
crossref_primary_10_3390_antiox12020317
crossref_primary_10_1007_s12275_022_1606_1
crossref_primary_10_1097_MD_0000000000021146
crossref_primary_10_3390_vaccines12050504
crossref_primary_10_5812_jjm_151057
crossref_primary_10_1136_bmjopen_2021_056502
crossref_primary_10_24931_2413_9432_2023_13_1_47_55
crossref_primary_10_3390_microorganisms12112326
crossref_primary_10_5937_mp73_35462
crossref_primary_10_1016_j_amjsurg_2019_08_011
crossref_primary_10_1186_s13027_021_00360_9
crossref_primary_10_3390_ijms22031219
crossref_primary_10_1002_rmv_2486
crossref_primary_10_1016_j_jcv_2025_105779
crossref_primary_10_1016_j_coms_2020_04_002
crossref_primary_10_1016_j_fertnstert_2020_07_006
crossref_primary_10_1016_j_apm_2022_08_017
crossref_primary_10_1038_s41564_022_01177_x
crossref_primary_10_1016_j_mcna_2020_09_008
crossref_primary_10_3390_vaccines10081274
crossref_primary_10_1016_j_rdc_2022_02_001
crossref_primary_10_1016_j_reumae_2023_07_004
crossref_primary_10_1186_s12885_021_08010_4
crossref_primary_10_1080_14737167_2025_2451732
crossref_primary_10_1038_s41435_022_00192_6
crossref_primary_10_22627_2072_8107_2025_24_1_37_42
crossref_primary_10_1002_puh2_126
crossref_primary_10_1016_j_genrep_2020_100958
crossref_primary_10_1159_000497617
crossref_primary_10_1016_j_jadohealth_2025_01_011
crossref_primary_10_1016_j_sbsr_2023_100562
crossref_primary_10_2217_fvl_2023_0086
crossref_primary_10_3390_curroncol29050303
crossref_primary_10_3892_ijo_2018_4518
crossref_primary_10_1007_s10549_024_07388_6
crossref_primary_10_1016_j_coi_2020_01_006
crossref_primary_10_3103_S0891416821040066
crossref_primary_10_1016_j_vaccine_2020_11_008
crossref_primary_10_3390_nu11092059
crossref_primary_10_70749_ijbr_v3i1_523
crossref_primary_10_1186_s12885_024_13013_y
crossref_primary_10_1016_j_vaccine_2019_11_046
crossref_primary_10_1016_j_ygyno_2020_04_698
crossref_primary_10_1111_febs_15217
crossref_primary_10_1080_21645515_2022_2126251
crossref_primary_10_1089_whr_2024_0121
crossref_primary_10_1097_LGT_0000000000000625
crossref_primary_10_1016_j_virol_2023_02_003
crossref_primary_10_1016_j_pmedr_2021_101438
crossref_primary_10_1016_j_pmedr_2022_101734
crossref_primary_10_1186_s12905_023_02196_4
Cites_doi 10.1001/jamaoncol.2015.0735
10.1001/jama.2012.101
10.1016/j.ejca.2014.07.018
10.1016/S1470-2045(10)70230-8
10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
10.1002/ijc.27485
10.1186/1471-2334-13-39
10.1007/s12105-012-0372-5
10.1186/s13027-017-0129-6
10.1099/jgv.0.000727
10.1097/OLQ.0b013e3181c94a3b
10.1093/jnci/djv403
10.1093/cid/ciw354
10.1016/j.vaccine.2012.04.108
10.1016/S1473-3099(14)71073-4
10.1093/jnci/dji187
10.1016/j.eururo.2015.12.007
10.1016/j.ejca.2013.06.033
10.1016/j.ejca.2015.06.001
10.1016/j.vaccine.2012.07.055
10.1016/S2214-109X(16)30143-7
10.1016/S2214-109X(16)30099-7
10.1007/s11904-014-0224-x
10.1002/ijc.28963
10.1016/j.ejca.2013.04.024
10.1086/657321
10.1002/ijc.30716
10.1002/ijc.29082
10.1016/S1470-2045(09)70096-8
ContentType Journal Article
Copyright 2017
Copyright © 2017. Published by Elsevier Ltd.
Copyright_xml – notice: 2017
– notice: Copyright © 2017. Published by Elsevier Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.bpobgyn.2017.08.006
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-1932
EndPage 26
ExternalDocumentID 29037457
10_1016_j_bpobgyn_2017_08_006
S1521693417301244
Genre Journal Article
Review
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5VS
6J9
6PF
7-5
71M
8P~
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
ROL
RPZ
SDF
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
Z5R
~G-
AACTN
AAIAV
ABLVK
ABYKQ
AFKWA
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
AAYXX
AFCTW
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
~HD
ID FETCH-LOGICAL-c419t-de0dcef369f8c0d848610ec0e7de931e5ebda0f0c5b9882a3ac54dac5d2ef1943
IEDL.DBID .~1
ISSN 1521-6934
1532-1932
IngestDate Sun Sep 28 02:04:19 EDT 2025
Wed Feb 19 02:43:35 EST 2025
Thu Apr 24 23:06:28 EDT 2025
Tue Jul 01 02:42:59 EDT 2025
Fri Feb 23 02:30:24 EST 2024
Tue Aug 26 18:36:49 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Prevention
Attributable fraction
Papillomavirus vaccines
Human papillomavirus
Time trends
Cancer
Language English
License Copyright © 2017. Published by Elsevier Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c419t-de0dcef369f8c0d848610ec0e7de931e5ebda0f0c5b9882a3ac54dac5d2ef1943
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0003-3943-0326
PMID 29037457
PQID 1952109432
PQPubID 23479
PageCount 13
ParticipantIDs proquest_miscellaneous_1952109432
pubmed_primary_29037457
crossref_citationtrail_10_1016_j_bpobgyn_2017_08_006
crossref_primary_10_1016_j_bpobgyn_2017_08_006
elsevier_sciencedirect_doi_10_1016_j_bpobgyn_2017_08_006
elsevier_clinicalkey_doi_10_1016_j_bpobgyn_2017_08_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2018
2018-02-00
2018-Feb
20180201
PublicationDateYYYYMMDD 2018-02-01
PublicationDate_xml – month: 02
  year: 2018
  text: February 2018
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Best practice & research. Clinical obstetrics & gynaecology
PublicationTitleAlternate Best Pract Res Clin Obstet Gynaecol
PublicationYear 2018
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Patel, Wagner, Singhal (bib29) 2013 Jan 25; 13
Serrano, de Sanjosé, Tous (bib34) 2015 Sep; 51
Gillison, Broutian, Pickard (bib15) 2012 Feb 15; 307
Vaccarella, Lortet-Tieulent, Plummer (bib18) 1990 2013 Oct; 49
Bruni, Diaz, Barrionuevo-Rosas (bib36) 2016 Jul; 4
Khan, Castle, Lorincz (bib5) 2005 Jul 20; 97
Forman, de Martel, Lacey (bib31) 2012 Nov 20; 30
Fitzmaurice, Dicker, Pain (bib20) 2015 Jul; 1
de Martel, Plummer, Vignat (bib7) 2017 Aug 15; 141
Schim van der Loeff, Mooij, Richel (bib12) 2014 Sep; 11
de Sanjose, Quint, Alemany (bib19) 2010 Nov; 11
Castellsagué, Alemany, Quer (bib28) 2016 Jan 28; 108
World Heath Organization (WHO), WHO department on immunization, vaccines and biologicals, World Health Organization, Geneva, [Internet]. [Cited 2017 July 20]. Available from
Walboomers, Jacobs, Manos (bib2) 1999 Sep; 189
Kreimer, Bhatia, Messeguer (bib13) 2010 Jun; 37
Bouvard, Baan, Straif (bib4) 2009 Apr; 10
IARC (bib1) 2011; vol. 100
Islami, Ferlay, Lortet-Tieulent (bib21) 2017 Jun 1; 46
Ervik, Lam, Ferlay (bib16) 2016
Alemany, Saunier, Alvarado-Cabrero (bib26) 2015 Jan 1; 136
Bruni, Barrionuevo-Rosas, Albero (bib8) April 2017; 19
Venuti, Paolini (bib22) 2012 Jul; 6
Plummer, de Martel, Vignat (bib6) 2016 Sep; 4
Hartwig, St Guily, Dominiak-Felden (bib23) 2017; 12
Bruni, Diaz, Castellsagué (bib9) 2010 Dec 15; 202
de Sanjosé, Alemany, Ordi (bib24) 2013 Nov; 49
Alemany, Cubilla, Halec (bib27) 2016 May; 69
Buckley, Henschke, Maayan (bib30) 2016
Giuliano, Nyitray, Kreimer (bib11) 2015 Jun 15; 136
Drolet, Bénard, Boily (bib37) 2015 May; 15
.
Schiller, Castellsagué, Garland (bib33) 2012 Nov 20; 30
Wood, Bain, Smith (bib14) 2017 Apr; 98
Alemany, Saunier, Tinoco (bib25) 2014 Nov; 50
Guan, Howell-Jones, Li (bib10) 2012 Nov 15; 131
(bib17) 2013
World Health Organization (WHO) (bib3) 2017
Garland, Kjaer, Muñoz (bib32) 2016 Aug 15; 63
Vaccarella (10.1016/j.bpobgyn.2017.08.006_bib18) 1990; 49
10.1016/j.bpobgyn.2017.08.006_bib35
Wood (10.1016/j.bpobgyn.2017.08.006_bib14) 2017; 98
Hartwig (10.1016/j.bpobgyn.2017.08.006_bib23) 2017; 12
IARC (10.1016/j.bpobgyn.2017.08.006_bib1) 2011; vol. 100
Schiller (10.1016/j.bpobgyn.2017.08.006_bib33) 2012; 30
Schim van der Loeff (10.1016/j.bpobgyn.2017.08.006_bib12) 2014; 11
Guan (10.1016/j.bpobgyn.2017.08.006_bib10) 2012; 131
Giuliano (10.1016/j.bpobgyn.2017.08.006_bib11) 2015; 136
Alemany (10.1016/j.bpobgyn.2017.08.006_bib26) 2015; 136
Castellsagué (10.1016/j.bpobgyn.2017.08.006_bib28) 2016; 108
Gillison (10.1016/j.bpobgyn.2017.08.006_bib15) 2012; 307
Patel (10.1016/j.bpobgyn.2017.08.006_bib29) 2013; 13
de Sanjosé (10.1016/j.bpobgyn.2017.08.006_bib24) 2013; 49
Buckley (10.1016/j.bpobgyn.2017.08.006_bib30) 2016
Plummer (10.1016/j.bpobgyn.2017.08.006_bib6) 2016; 4
Garland (10.1016/j.bpobgyn.2017.08.006_bib32) 2016; 63
Bouvard (10.1016/j.bpobgyn.2017.08.006_bib4) 2009; 10
Khan (10.1016/j.bpobgyn.2017.08.006_bib5) 2005; 97
World Health Organization (WHO) (10.1016/j.bpobgyn.2017.08.006_bib3) 2017
de Martel (10.1016/j.bpobgyn.2017.08.006_bib7) 2017; 141
Alemany (10.1016/j.bpobgyn.2017.08.006_bib25) 2014; 50
Alemany (10.1016/j.bpobgyn.2017.08.006_bib27) 2016; 69
Kreimer (10.1016/j.bpobgyn.2017.08.006_bib13) 2010; 37
Islami (10.1016/j.bpobgyn.2017.08.006_bib21) 2017; 46
Bruni (10.1016/j.bpobgyn.2017.08.006_bib9) 2010; 202
Venuti (10.1016/j.bpobgyn.2017.08.006_bib22) 2012; 6
Fitzmaurice (10.1016/j.bpobgyn.2017.08.006_bib20) 2015; 1
Serrano (10.1016/j.bpobgyn.2017.08.006_bib34) 2015; 51
Walboomers (10.1016/j.bpobgyn.2017.08.006_bib2) 1999; 189
(10.1016/j.bpobgyn.2017.08.006_bib17) 2013
Drolet (10.1016/j.bpobgyn.2017.08.006_bib37) 2015; 15
Bruni (10.1016/j.bpobgyn.2017.08.006_bib36) 2016; 4
Forman (10.1016/j.bpobgyn.2017.08.006_bib31) 2012; 30
Ervik (10.1016/j.bpobgyn.2017.08.006_bib16) 2016
de Sanjose (10.1016/j.bpobgyn.2017.08.006_bib19) 2010; 11
Bruni (10.1016/j.bpobgyn.2017.08.006_bib8) 2017; 19
References_xml – start-page: 18
  year: 2016
  ident: bib30
  article-title: Anogenital warts: incidence, prevalence, self-reported history and quality of life
– volume: 69
  start-page: 953
  year: 2016 May
  end-page: 961
  ident: bib27
  article-title: Role of human papillomavirus in penile carcinomas worldwide
  publication-title: Eur Urol
– volume: 13
  start-page: 39
  year: 2013 Jan 25
  ident: bib29
  article-title: Systematic review of the incidence and prevalence of genital warts
  publication-title: BMC Infect Dis
– volume: 4
  start-page: e453
  year: 2016 Jul
  end-page: 463
  ident: bib36
  article-title: Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
  publication-title: Lancet Glob Health
– volume: 15
  start-page: 565
  year: 2015 May
  end-page: 580
  ident: bib37
  article-title: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
  publication-title: Lancet Infect Dis
– volume: 6
  start-page: S63
  year: 2012 Jul
  end-page: S74
  ident: bib22
  article-title: HPV detection methods in head and neck cancer
  publication-title: Head Neck Pathol
– volume: 63
  start-page: 519
  year: 2016 Aug 15
  end-page: 527
  ident: bib32
  article-title: Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience
  publication-title: Clin Infect Dis
– volume: 202
  start-page: 1789
  year: 2010 Dec 15
  end-page: 1799
  ident: bib9
  article-title: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings
  publication-title: J Infect Dis
– volume: 307
  start-page: 693
  year: 2012 Feb 15
  end-page: 703
  ident: bib15
  article-title: Prevalence of oral HPV infection in the United States, 2009-2010
  publication-title: JAMA
– volume: 50
  start-page: 2846
  year: 2014 Nov
  end-page: 2854
  ident: bib25
  article-title: Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples
  publication-title: Eur J Cancer
– volume: 19
  year: April 2017
  ident: bib8
  article-title: ICO/IARC information Centre on papillomavirus and cancer (HPV information Centre). Human papillomavirus and related diseases in the world
  publication-title: Summ Rep
– volume: 12
  start-page: 19
  year: 2017
  ident: bib23
  article-title: Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
  publication-title: Infect Agent Cancer
– year: 2017
  ident: bib3
  article-title: Human papillomavirus vaccines WHO position paper
– volume: vol. 100
  year: 2011
  ident: bib1
  publication-title: Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents
– volume: 11
  start-page: 1048
  year: 2010 Nov
  end-page: 1056
  ident: bib19
  article-title: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
  publication-title: Lancet Oncol
– volume: 51
  start-page: 1732
  year: 2015 Sep
  end-page: 1741
  ident: bib34
  article-title: Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions
  publication-title: Eur J Cancer
– volume: 97
  start-page: 1072
  year: 2005 Jul 20
  end-page: 1079
  ident: bib5
  article-title: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
  publication-title: J Natl Cancer Inst
– volume: 49
  start-page: 3262
  year: 1990 2013 Oct
  end-page: 3273
  ident: bib18
  article-title: Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors
  publication-title: Eur J Cancer
– volume: 10
  start-page: 321
  year: 2009 Apr
  end-page: 322
  ident: bib4
  article-title: A review of human carcinogens–part B: biological agents
  publication-title: Lancet Oncol
– volume: 108
  year: 2016 Jan 28
  ident: bib28
  article-title: HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients
  publication-title: J Natl Cancer Inst
– volume: 136
  start-page: 2752
  year: 2015 Jun 15
  end-page: 2760
  ident: bib11
  article-title: EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection
  publication-title: Int J Cancer
– volume: 136
  start-page: 98
  year: 2015 Jan 1
  end-page: 107
  ident: bib26
  article-title: Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide
  publication-title: Int J Cancer
– volume: 30
  start-page: F123
  year: 2012 Nov 20
  end-page: F138
  ident: bib33
  article-title: A review of clinical trials of human papillomavirus prophylactic vaccines
  publication-title: Vaccine
– reference: .
– volume: 46
  start-page: 924
  year: 2017 Jun 1
  end-page: 938
  ident: bib21
  article-title: International trends in anal cancer incidence rates
  publication-title: Int J Epidemiol
– volume: 30
  start-page: F12
  year: 2012 Nov 20
  end-page: F23
  ident: bib31
  article-title: Global burden of human papillomavirus and related diseases
  publication-title: Vaccine
– volume: 4
  start-page: e609
  year: 2016 Sep
  end-page: 616
  ident: bib6
  article-title: Global burden of cancers attributable to infections in 2012: a synthetic analysis
  publication-title: Lancet Glob Health
– volume: 131
  start-page: 2349
  year: 2012 Nov 15
  end-page: 2359
  ident: bib10
  article-title: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
  publication-title: Int J Cancer
– volume: 98
  start-page: 519
  year: 2017 Apr
  end-page: 526
  ident: bib14
  article-title: Oral human papillomavirus infection incidence and clearance: a systematic review of the literature
  publication-title: J Gen Virol
– volume: 189
  start-page: 12
  year: 1999 Sep
  end-page: 19
  ident: bib2
  article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  publication-title: J Pathol
– year: 2016
  ident: bib16
  article-title: Cancer Today
– volume: 11
  start-page: 250
  year: 2014 Sep
  end-page: 262
  ident: bib12
  article-title: HPV and anal cancer in HIV-infected individuals: a review
  publication-title: Curr HIV/AIDS Rep
– volume: 37
  start-page: 386
  year: 2010 Jun
  end-page: 391
  ident: bib13
  article-title: Oral human papillomavirus in healthy individuals: a systematic review of the literature
  publication-title: Sex Transm Dis
– volume: 1
  start-page: 505
  year: 2015 Jul
  end-page: 527
  ident: bib20
  article-title: The global burden of cancer 2013
  publication-title: JAMA Oncol
– year: 2013
  ident: bib17
  publication-title: Cancer incidence in five Continents, vol. X (electronic version)
– volume: 49
  start-page: 3450
  year: 2013 Nov
  end-page: 3461
  ident: bib24
  article-title: Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
  publication-title: Eur J Cancer
– reference: World Heath Organization (WHO), WHO department on immunization, vaccines and biologicals, World Health Organization, Geneva, [Internet]. [Cited 2017 July 20]. Available from:
– volume: 141
  start-page: 664
  year: 2017 Aug 15
  end-page: 670
  ident: bib7
  article-title: Worldwide burden of cancer attributable to HPV by site, country and HPV type
  publication-title: Int J Cancer
– year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib16
– volume: 1
  start-page: 505
  issue: 4
  year: 2015
  ident: 10.1016/j.bpobgyn.2017.08.006_bib20
  article-title: The global burden of cancer 2013
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2015.0735
– year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib3
– volume: 307
  start-page: 693
  issue: 7
  year: 2012
  ident: 10.1016/j.bpobgyn.2017.08.006_bib15
  article-title: Prevalence of oral HPV infection in the United States, 2009-2010
  publication-title: JAMA
  doi: 10.1001/jama.2012.101
– volume: 50
  start-page: 2846
  issue: 16
  year: 2014
  ident: 10.1016/j.bpobgyn.2017.08.006_bib25
  article-title: Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2014.07.018
– volume: 11
  start-page: 1048
  issue: 11
  year: 2010
  ident: 10.1016/j.bpobgyn.2017.08.006_bib19
  article-title: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70230-8
– volume: 189
  start-page: 12
  issue: 1
  year: 1999
  ident: 10.1016/j.bpobgyn.2017.08.006_bib2
  article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  publication-title: J Pathol
  doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
– volume: 131
  start-page: 2349
  issue: 10
  year: 2012
  ident: 10.1016/j.bpobgyn.2017.08.006_bib10
  article-title: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27485
– volume: 13
  start-page: 39
  year: 2013
  ident: 10.1016/j.bpobgyn.2017.08.006_bib29
  article-title: Systematic review of the incidence and prevalence of genital warts
  publication-title: BMC Infect Dis
  doi: 10.1186/1471-2334-13-39
– volume: 6
  start-page: S63
  issue: Suppl. 1
  year: 2012
  ident: 10.1016/j.bpobgyn.2017.08.006_bib22
  article-title: HPV detection methods in head and neck cancer
  publication-title: Head Neck Pathol
  doi: 10.1007/s12105-012-0372-5
– volume: 12
  start-page: 19
  year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib23
  article-title: Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
  publication-title: Infect Agent Cancer
  doi: 10.1186/s13027-017-0129-6
– volume: 98
  start-page: 519
  issue: 4
  year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib14
  article-title: Oral human papillomavirus infection incidence and clearance: a systematic review of the literature
  publication-title: J Gen Virol
  doi: 10.1099/jgv.0.000727
– volume: 37
  start-page: 386
  issue: 6
  year: 2010
  ident: 10.1016/j.bpobgyn.2017.08.006_bib13
  article-title: Oral human papillomavirus in healthy individuals: a systematic review of the literature
  publication-title: Sex Transm Dis
  doi: 10.1097/OLQ.0b013e3181c94a3b
– volume: 108
  issue: 6
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib28
  article-title: HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djv403
– volume: 63
  start-page: 519
  issue: 4
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib32
  article-title: Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw354
– volume: 30
  start-page: F123
  issue: Suppl. 5
  year: 2012
  ident: 10.1016/j.bpobgyn.2017.08.006_bib33
  article-title: A review of clinical trials of human papillomavirus prophylactic vaccines
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.04.108
– ident: 10.1016/j.bpobgyn.2017.08.006_bib35
– volume: 15
  start-page: 565
  issue: 5
  year: 2015
  ident: 10.1016/j.bpobgyn.2017.08.006_bib37
  article-title: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(14)71073-4
– volume: 97
  start-page: 1072
  issue: 14
  year: 2005
  ident: 10.1016/j.bpobgyn.2017.08.006_bib5
  article-title: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dji187
– volume: 69
  start-page: 953
  issue: 5
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib27
  article-title: Role of human papillomavirus in penile carcinomas worldwide
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2015.12.007
– volume: 49
  start-page: 3450
  issue: 16
  year: 2013
  ident: 10.1016/j.bpobgyn.2017.08.006_bib24
  article-title: Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.06.033
– volume: 51
  start-page: 1732
  issue: 13
  year: 2015
  ident: 10.1016/j.bpobgyn.2017.08.006_bib34
  article-title: Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.06.001
– volume: 30
  start-page: F12
  issue: Suppl. 5
  year: 2012
  ident: 10.1016/j.bpobgyn.2017.08.006_bib31
  article-title: Global burden of human papillomavirus and related diseases
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.07.055
– year: 2013
  ident: 10.1016/j.bpobgyn.2017.08.006_bib17
– start-page: 18
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib30
– volume: vol. 100
  year: 2011
  ident: 10.1016/j.bpobgyn.2017.08.006_bib1
– volume: 4
  start-page: e609
  issue: 9
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib6
  article-title: Global burden of cancers attributable to infections in 2012: a synthetic analysis
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(16)30143-7
– volume: 4
  start-page: e453
  issue: 7
  year: 2016
  ident: 10.1016/j.bpobgyn.2017.08.006_bib36
  article-title: Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(16)30099-7
– volume: 11
  start-page: 250
  issue: 3
  year: 2014
  ident: 10.1016/j.bpobgyn.2017.08.006_bib12
  article-title: HPV and anal cancer in HIV-infected individuals: a review
  publication-title: Curr HIV/AIDS Rep
  doi: 10.1007/s11904-014-0224-x
– volume: 136
  start-page: 98
  issue: 1
  year: 2015
  ident: 10.1016/j.bpobgyn.2017.08.006_bib26
  article-title: Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28963
– volume: 49
  start-page: 3262
  issue: 15
  year: 1990
  ident: 10.1016/j.bpobgyn.2017.08.006_bib18
  article-title: Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.04.024
– volume: 46
  start-page: 924
  issue: 3
  year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib21
  article-title: International trends in anal cancer incidence rates
  publication-title: Int J Epidemiol
– volume: 202
  start-page: 1789
  issue: 12
  year: 2010
  ident: 10.1016/j.bpobgyn.2017.08.006_bib9
  article-title: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings
  publication-title: J Infect Dis
  doi: 10.1086/657321
– volume: 141
  start-page: 664
  issue: 4
  year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib7
  article-title: Worldwide burden of cancer attributable to HPV by site, country and HPV type
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30716
– volume: 136
  start-page: 2752
  issue: 12
  year: 2015
  ident: 10.1016/j.bpobgyn.2017.08.006_bib11
  article-title: EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29082
– volume: 19
  year: 2017
  ident: 10.1016/j.bpobgyn.2017.08.006_bib8
  article-title: ICO/IARC information Centre on papillomavirus and cancer (HPV information Centre). Human papillomavirus and related diseases in the world
  publication-title: Summ Rep
– volume: 10
  start-page: 321
  issue: 4
  year: 2009
  ident: 10.1016/j.bpobgyn.2017.08.006_bib4
  article-title: A review of human carcinogens–part B: biological agents
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70096-8
SSID ssj0033925
Score 2.6282685
SecondaryResourceType review_article
Snippet Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 14
SubjectTerms Age Distribution
Anus Neoplasms - epidemiology
Anus Neoplasms - prevention & control
Anus Neoplasms - virology
Attributable fraction
Cancer
Female
Global Burden of Disease - statistics & numerical data
Head and Neck Neoplasms - epidemiology
Head and Neck Neoplasms - prevention & control
Head and Neck Neoplasms - virology
Human papillomavirus
Humans
Incidence
Male
Papillomaviridae
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines
Penile Neoplasms - epidemiology
Penile Neoplasms - prevention & control
Penile Neoplasms - virology
Prevention
Time trends
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - prevention & control
Uterine Cervical Neoplasms - virology
Title Epidemiology and burden of HPV-related disease
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1521693417301244
https://dx.doi.org/10.1016/j.bpobgyn.2017.08.006
https://www.ncbi.nlm.nih.gov/pubmed/29037457
https://www.proquest.com/docview/1952109432
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6iIF7Et-tjqeC1u02btM1RFmV9IuqKt5A0iewi3UXXgxd_uzNtuiIoipeWlg5tJvMqM_MNIYfgFKjOsyzMuIlC0MQ0FEZhDj62VqUKAViw2uIq7Q_Y2QN_mCO9phcGyyq97a9temWt_Z2u52Z3Mhx2b9HzpAKsMAopeCnsYGcZynrnfVbmkYD_5xVmakxDfPqzi6c76ujJWD--IQwqzSokTxx89L1_-in-rPzQyQpZ9gFkcFR_4yqZs-UaWbz0KfJ10jn-nPn6FqjSBLrqVAjGLuhf34dV84o1gc_MbJDByfFdrx_6oQhhwaiYhsZGprAuSYXLi8jkLIcAyBaRzYwVCbXcaqMiFxVcC4ieVaIKzgwcTGwdFSzZJPPluLTbJODWOarwDy9yDHRZQbQYO8FjrVkSZ3GLsIYVsvCI4Ti44kk2pWEj6TkokYMSB1pGaYt0ZmSTGjLjN4K04bNs-kHBgkkw6r8R5jPCL0LzF9KDZkMlKBRmSVRpx68vkgIDKNZbwvq36p2eLSMWCNfDs53_v3iXLMFVXhd-75H56fOr3Ye4ZqrbleC2ycJR7-biGs-n5_2rD9iD9xg
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-QL2Ib9dnBa_dbdqkbY4iK6uuIvjAW0iaRBTpLrp78OJvd6ZNVwRF8dJD26HNdDLzlZn5hpBDCApU51kWZtxEIezENBRGYQ4-tlalCglYsNriMu3dsrN7fj9FjpteGCyr9L6_9umVt_ZnOl6bneHjY-caI08qwAujkUKUmiazDMccgFG33yd1HgkAAF6RpsY0xNs_23g6T209HOiHN-RBpVlF5YmTj74PUD8B0CoQnSyRRY8gg6P6JZfJlC1XyNyFz5Gvknb3c-jrW6BKE-iqVSEYuKB3dRdW3SvWBD41s0ZuT7o3x73QT0UIC0bFKDQ2MoV1SSpcXkQmZzkgIFtENjNWJNRyq42KXFRwLQA-q0QVnBk4mNg6KliyTmbKQWk3ScCtc1ThL17kGGxmBXAxdoLHWrMkzuIWYY0qZOEpw3FyxbNsasOepNegRA1KnGgZpS3SnogNa86M3wTSRs-yaQgFFybBq_8mmE8Ev1jNX0QPmg8qYUdhmkSVdjB-lRQUQLHgEta_UX_pyTJigXw9PNv6_4P3yXzv5qIv-6eX59tkAa7kdRX4DpkZvYztLoCckd6rjPgDs133DA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epidemiology+and+burden+of+HPV-related+disease&rft.jtitle=Best+practice+%26+research.+Clinical+obstetrics+%26+gynaecology&rft.au=Serrano%2C+Beatriz&rft.au=Brotons%2C+Mar%C3%ADa&rft.au=Bosch%2C+Francesc+Xavier&rft.au=Bruni%2C+Laia&rft.date=2018-02-01&rft.pub=Elsevier+Ltd&rft.issn=1521-6934&rft.eissn=1532-1932&rft.volume=47&rft.spage=14&rft.epage=26&rft_id=info:doi/10.1016%2Fj.bpobgyn.2017.08.006&rft.externalDocID=S1521693417301244
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1521-6934&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1521-6934&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1521-6934&client=summon